| P2093 | author name string | Jean-Francois Dufour | |
| | Juliette Martin | |
| P2860 | cites work | DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development | Q22010765 |
| | TIP49b, a new RuvB-like DNA helicase, is included in a complex together with another RuvB-like DNA helicase, TIP49a | Q22253154 |
| | Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase | Q22254584 |
| | Aberrant gene expression in human non small cell lung carcinoma cells exposed to demethylating agent 5-aza-2 '-deoxycytidine | Q24170503 |
| | Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity | Q24290192 |
| | The histidine triad protein Hint1 triggers apoptosis independent of its enzymatic activity | Q24296818 |
| | The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation | Q24297959 |
| | Physical and functional interaction between HCV core protein and the different p73 isoforms | Q24301094 |
| | Role of L2DTL, cell cycle-regulated nuclear and centrosome protein, in aggressive hepatocellular carcinoma | Q24315694 |
| | Twenty proteins containing a C-terminal SOCS box form five structural classes | Q24317684 |
| | Zf9, a Kruppel-like transcription factor up-regulated in vivo during early hepatic fibrosis | Q24319960 |
| | A microRNA expression signature of human solid tumors defines cancer gene targets | Q24541455 |
| | WWOX: a candidate tumor suppressor gene involved in multiple tumor types | Q24555184 |
| | A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors | Q24568224 |
| | Gene expression profiling predicts clinical outcome of prostate cancer | Q24594253 |
| | Pontin52 and reptin52 function as antagonistic regulators of beta-catenin signalling activity | Q24597019 |
| | Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers | Q24625794 |
| | Downregulation of miR-122 in the rodent and human hepatocellular carcinomas | Q24631076 |
| | Functional association between Wwox tumor suppressor protein and p73, a p53 homolog | Q24633799 |
| | Adenosine monophosphoramidase activity of Hint and Hnt1 supports function of Kin28, Ccl1, and Tfb3 | Q24642988 |
| | Frequent downregulation and loss of WWOX gene expression in human hepatocellular carcinoma | Q24647959 |
| | The links between axin and carcinogenesis | Q24672469 |
| | Muir-Torre-like syndrome in Fhit-deficient mice | Q24676755 |
| | Deletion, mutation, and loss of expression of KLF6 in human prostate cancer | Q24684163 |
| | Aberrant Promoter Methylation Profiles of Tumor Suppressor Genes in Hepatocellular Carcinoma | Q27478395 |
| | MicroRNA gene expression deregulation in human breast cancer | Q27860690 |
| | A microRNA polycistron as a potential human oncogene | Q27860720 |
| | Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA | Q27861124 |
| | MicroRNA expression profiles classify human cancers | Q28032481 |
| | Cloning of the human homolog of conductin (AXIN2), a gene mapping to chromosome 17q23-q24 | Q28137873 |
| | AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1 | Q28145752 |
| | Reduced accumulation of specific microRNAs in colorectal neoplasia | Q28211976 |
| | p53 gene in treatment of hepatic carcinoma: status quo. | Q36764842 |
| | Sequence of the FRA3B common fragile region: implications for the mechanism of FHIT deletion | Q36827321 |
| | Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent. | Q38294565 |
| | Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets | Q38400913 |
| | Expression and hypermethylation of p27 kip1 in hepatocarcinogenesis | Q39676737 |
| | Hepatitis B virus X protein activates transcription factor NF-kappa B without a requirement for protein kinase C | Q40064034 |
| | TIP30 mutant derived from hepatocellular carcinoma specimens promotes growth of HepG2 cells through up-regulation of N-cadherin | Q40144609 |
| | Aberrant epigenetic modifications in hepatocarcinogenesis induced by hepatitis B virus X protein | Q40149729 |
| | KLF6 transcription factor protects hepatocellular carcinoma-derived cells from apoptosis | Q40161488 |
| | Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma | Q40166887 |
| | Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation | Q40167589 |
| | Inhibition of breast cancer cell growth in vitro and in vivo: effect of restoration of Wwox expression | Q40187900 |
| | Different levels of p53 induced either apoptosis or cell cycle arrest in a doxycycline-regulated hepatocellular carcinoma cell line in vitro | Q40190021 |
| | KLF6 degradation after apoptotic DNA damage. | Q40206947 |
| | TIP30 inhibits growth of HCC cell lines and inhibits HCC xenografts in mice in combination with 5-FU. | Q40262791 |
| | E-cadherin is a novel transcriptional target of the KLF6 tumor suppressor. | Q40279481 |
| | Effect of promoter methylation of the p16 gene on phosphorylation of retinoblastoma gene product and growth of hepatocellular carcinoma cells | Q40357085 |
| | EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer | Q40361923 |
| | Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma | Q40399429 |
| | Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma | Q40503818 |
| | Estrogen up-regulates hepatic expression of suppressors of cytokine signaling-2 and -3 in vivo and in vitro | Q40524068 |
| | Parkin gene alterations in hepatocellular carcinoma | Q40564245 |
| | The alteration of PTEN tumor suppressor expression and its association with the histopathological features of human primary hepatocellular carcinoma | Q40596882 |
| | Intensive hypermethylation of the CpG island of Ras association domain family 1A in hepatitis B virus-associated hepatocellular carcinomas. | Q40636979 |
| | High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1-DNA adduct levels in human hepatocellular carcinoma | Q40701324 |
| | Innate form of HCV core protein plays an important role in the localization and the function of HCV core protein | Q40726283 |
| | Introduction of a murine p53 mutation corresponding to human codon 249 into a murine hepatocyte cell line results in growth advantage, but not in transformation | Q41291537 |
| | Apoptosis of rat vascular smooth muscle cells is regulated by p53-dependent and -independent pathways. | Q41319468 |
| | Hepatocarcinoma-specific mutant p53-249ser induces mitotic activity but has no effect on transforming growth factor beta 1-mediated apoptosis | Q41473731 |
| | Activation of mammalian DNA methyltransferase by cleavage of a Zn binding regulatory domain | Q41529080 |
| | Hepatitis B Virus X protein modulates the expression of PTEN by inhibiting the function of p53, a transcriptional activator in liver cells. | Q42162960 |
| | Loss of one p53 allele results in four-fold reduction of p53 mRNA and protein: a basis for p53 haplo-insufficiency | Q42490237 |
| | Hepatitis C virus core protein represses the p21 promoter through inhibition of a TGF-beta pathway | Q42811309 |
| | Cooperative repression of cyclin-dependent kinase inhibitor p21 gene expression by hepatitis B virus X protein and hepatitis C virus core protein | Q42815629 |
| | Alterations of the fragile histidine triad gene in hepatitis C virus-associated hepatocellular carcinoma. | Q42989581 |
| | Loss of E-cadherin mRNA and gain of osteopontin mRNA are useful markers for detecting early recurrence of HCV-related hepatocellular carcinoma | Q42996730 |
| | p53 gene abnormalities are closely related to hepatoviral infections and occur at a late stage of hepatocarcinogenesis | Q43048803 |
| | Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma | Q43049041 |
| | High frequency of promoter hypermethylation of RASSF1A in tumor and plasma of patients with hepatocellular carcinoma | Q43562391 |
| | SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity | Q43590722 |
| | Ser-249 p53 mutations in plasma DNA of patients with hepatocellular carcinoma from The Gambia | Q43905055 |
| | Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. | Q44259986 |
| | Alterations in the common fragile site gene Parkin in ovarian and other cancers | Q44653680 |
| | FHIT mRNA and protein expression in hepatocellular carcinoma | Q44827323 |
| | Study of the PTEN gene expression and FAK phosphorylation in human hepatocarcinoma tissues and cell lines | Q45143602 |
| | Unique patterns of gene expression changes in liver after treatment of mice for 2 weeks with different known carcinogens and non-carcinogens | Q45200658 |
| | Downregulation of E-cadherin by hepatitis B virus X antigen in hepatocellullar carcinoma | Q45423109 |
| | High expression of p21WAF1/CIP1 is correlated with human hepatocellular carcinoma in patients with hepatitis C virus-associated chronic liver diseases | Q45732222 |
| | p73 overexpression and nuclear accumulation in hepatitis C virus-associated hepatocellular carcinoma | Q45732686 |
| | CpG island methylator phenotype association with elevated serum alpha-fetoprotein level in hepatocellular carcinoma | Q45865898 |
| | Hint1 is a haplo-insufficient tumor suppressor in mice | Q46722746 |
| | Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa | Q46754150 |
| | Methylation status of suppressor of cytokine signaling-1 gene in hepatocellular carcinoma | Q47243980 |
| | Disregulation of E-cadherin in transgenic mouse models of liver cancer | Q47281445 |
| | Disruption of p53-p21/WAF1 cell cycle pathway contributes to progression and worse clinical outcome of hepatocellular carcinoma. | Q47330816 |
| | KLF6, a candidate tumor suppressor gene mutated in prostate cancer | Q28213009 |
| | Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas | Q28213290 |
| | RASSF3 and NORE1: identification and cloning of two human homologues of the putative tumor suppressor gene RASSF1 | Q28215344 |
| | SOCS proteins: negative regulators of cytokine signaling | Q28216055 |
| | TIP30 deficiency increases susceptibility to tumorigenesis | Q28236068 |
| | The fragile genes FHIT and WWOX are inactivated coordinately in invasive breast carcinoma | Q28255650 |
| | NORE1B, a candidate tumor suppressor, is epigenetically silenced in human hepatocellular carcinoma | Q28300321 |
| | Hint2, a mitochondrial apoptotic sensitizer down-regulated in hepatocellular carcinoma | Q28386062 |
| | Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases | Q28507226 |
| | A rat RuvB-like protein, TIP49a, is a germ cell-enriched novel DNA helicase | Q28565902 |
| | Parkin binds to alpha/beta tubulin and increases their ubiquitination and degradation | Q28572388 |
| | Liver-targeted disruption of Apc in mice activates beta-catenin signaling and leads to hepatocellular carcinomas | Q28592004 |
| | The p53-mdm-2 autoregulatory feedback loop | Q28609811 |
| | Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas | Q29616243 |
| | The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice | Q29620765 |
| | Hint1 inhibits growth and activator protein-1 activity in human colon cancer cells. | Q30157975 |
| | Krüppel-like factor 6 is frequently down-regulated and induces apoptosis in non-small cell lung cancer cells. | Q30762846 |
| | Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. | Q30884723 |
| | A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes | Q33343251 |
| | The murine gene p27Kip1 is haplo-insufficient for tumour suppression | Q33574523 |
| | Promoter methylation of E-cadherin in hepatocellular carcinomas and dysplastic nodules | Q33599535 |
| | Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation | Q33889285 |
| | Signaling to p53: breaking the posttranslational modification code | Q33945840 |
| | Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in lung and cervical cancer cell lines | Q34019362 |
| | p27(Kip1): regulation and function of a haploinsufficient tumor suppressor and its misregulation in cancer. | Q34174341 |
| | p53 mutations cluster at codon 249 in hepatitis B virus-positive hepatocellular carcinomas from China | Q34233763 |
| | How hepatitis C virus counteracts the interferon response: the jury is still out on NS5A. | Q34250843 |
| | Kruppel-like factor 6 (KLF6) is a tumor-suppressor gene frequently inactivated in colorectal cancer. | Q34310233 |
| | Abrogation of p53-induced apoptosis by the hepatitis B virus X gene | Q34367126 |
| | Expression of fragile histidine triad in primary hepatocellular carcinoma and its relation with cell proliferation and apoptosis | Q34382649 |
| | Genotoxic and non-genotoxic pathways of p53 induction | Q34417108 |
| | The histidine triad protein Hint1 interacts with Pontin and Reptin and inhibits TCF-beta-catenin-mediated transcription | Q34433483 |
| | Hepatocellular carcinoma: from gene to public health. | Q34450751 |
| | Regulation of Kruppel-like factor 6 tumor suppressor activity by acetylation. | Q34460384 |
| | Abnormal methylation of the common PARK2 and PACRG promoter is associated with downregulation of gene expression in acute lymphoblastic leukemia and chronic myeloid leukemia | Q34467458 |
| | L2DTL/CDT2 and PCNA interact with p53 and regulate p53 polyubiquitination and protein stability through MDM2 and CUL4A/DDB1 complexes | Q34550320 |
| | p53-mediated cellular response to DNA damage in cells with replicative hepatitis B virus | Q34609247 |
| | Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma | Q34647028 |
| | The prognostic molecular markers in hepatocellular carcinoma | Q34668320 |
| | Quantitative evaluation of RASSF1A methylation in the non-lesional, regenerative and neoplastic liver | Q34681945 |
| | Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers | Q34935968 |
| | Inhibitory effect of tumor suppressor p33(ING1b) and its synergy with p53 gene in hepatocellular carcinoma | Q35010492 |
| | TP53 and liver carcinogenesis. | Q35078725 |
| | Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3 | Q35101216 |
| | Deletion of histidine triad nucleotide-binding protein 1/PKC-interacting protein in mice enhances cell growth and carcinogenesis | Q35146975 |
| | Small molecules that reactivate mutant p53. | Q35204556 |
| | PTEN: from pathology to biology | Q35208577 |
| | Down-regulation of PTEN expression due to loss of promoter activity in human hepatocellular carcinoma cell lines | Q35435345 |
| | The tumor-suppressor gene FHIT is involved in the regulation of apoptosis and in cell cycle control | Q35552007 |
| | Parkin and relatives: the RBR family of ubiquitin ligases | Q35777606 |
| | Targeting the p53-MDM2 interaction to treat cancer | Q35903526 |
| | Post-translational modification of p53 in tumorigenesis | Q35930703 |
| | Molecular mechanisms in hepatocellular carcinoma development | Q36066435 |
| | Loss of fragile histidine triad protein in human hepatocellular carcinoma | Q36179787 |
| | Association of low p16INK4a and p15INK4b mRNAs expression with their CpG islands methylation with human hepatocellular carcinogenesis | Q36213792 |
| | How microRNAs control cell division, differentiation and death | Q36229101 |
| | Roles of FHIT and WWOX fragile genes in cancer | Q36286636 |
| | Aberrant FHIT transcripts in hepatocellular carcinomas | Q36295106 |
| | Expression and altered subcellular localization of the cyclin-dependent kinase inhibitor p27Kip1 in hepatocellular carcinoma | Q36308092 |
| | Epigenetic instability and chromosomal instability in hepatocellular carcinoma | Q36411144 |
| | Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. | Q36497062 |
| | CpG methylation of MGMT and hMLH1 promoter in hepatocellular carcinoma associated with hepatitis viral infection. | Q36649118 |
| | p16 and p27 are functionally correlated during the progress of hepatocarcinogenesis | Q36691546 |
| | Hepatitis B virus integration, fragile sites, and hepatocarcinogenesis | Q36692164 |
| | Methylation-mediated silencing of SOCS-1 gene in hepatocellular carcinoma derived from cirrhosis | Q47389002 |
| | P14ARF gene alterations in human hepatocellular carcinoma. | Q47737415 |
| | Expression of DNA (5-cytosin)-methyltransferases (DNMTs) in hepatocellular carcinomas | Q47773243 |
| | Immunohistochemical analysis and mutational analyses of beta-catenin, Axin family and APC genes in hepatocellular carcinomas. | Q47809130 |
| | Nore1 inhibits tumor cell growth independent of Ras or the MST1/2 kinases | Q47984176 |
| | PTEN/MMAC1 mutations in hepatocellular carcinomas | Q48203168 |
| | Inactivation of SSI-1, a JAK/STAT inhibitor, in human hepatocellular carcinomas, as revealed by two-dimensional electrophoresis | Q48368105 |
| | Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. | Q51958786 |
| | Cell cycle regulators and human hepatocarcinogenesis. | Q52532853 |
| | Disruption of the p16/cyclin D1/retinoblastoma protein pathway in the majority of human hepatocellular carcinomas. | Q52543244 |
| | Cell-cycle inhibition by TNP-470 in an in vivo model of hepatocarcinoma is mediated by a p53 and p21WAF1/CIP1 mechanism. | Q53338395 |
| | Deletion of the SOCS3 gene in liver parenchymal cells promotes hepatitis-induced hepatocarcinogenesis. | Q53344106 |
| | Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. | Q53347351 |
| | p21Cip1 nullizygosity increases tumor metastasis in irradiated mice. | Q53378608 |
| | DNA methyltransferase expression and DNA hypermethylation in human hepatocellular carcinoma. | Q53622156 |
| | Aberrant p16INK4A RNA transcripts expressed in hepatocellular carcinoma cell lines regulate pRb phosphorylation by binding with CDK4, resulting in delayed cell cycle progression. | Q53651249 |
| | [Molecular biology and hepatocellular carcinoma: current status and future prospects] | Q53816195 |
| | [Clinicopathological significance of aberrant methylation of the fragile histidine triad gene in patients with hepatocellular carcinoma]. | Q54293888 |
| | Genetic inactivation of the APC gene contributes to the malignant progression of sporadic hepatocellular carcinoma: a case report. | Q54458047 |
| | Acquired expression of p27 is a favorable prognostic indicator in patients with hepatocellular carcinoma | Q57009239 |
| | Aberrant fragile histidine triad gene transcripts in primary hepatocellular carcinoma and liver cirrhosis | Q57011705 |
| | Alterations of the FHIT gene in human hepatocellular carcinoma. | Q64923037 |
| | Geographic variation of p53 mutational profile in nonmalignant human liver | Q72442935 |
| | Hepatitis B x antigen and p53 are associated in vitro and in liver tissues from patients with primary hepatocellular carcinoma | Q72966947 |
| | NORE1A, a homologue of RASSF1A tumour suppressor gene is inactivated in human cancers | Q72992695 |
| | Expression of DNA methyltransferases in multistep hepatocarcinogenesis | Q73046464 |
| | Combined loss of expression of O6-methylguanine-DNA methyltransferase and hMLH1 accelerates progression of hepatocellular carcinoma | Q73083524 |
| | Progressive telomere shortening and telomerase reactivation during hepatocellular carcinogenesis | Q73136433 |
| | [Interactive pathway of ARF-mdm2-p53] | Q73166377 |
| | Frequent epigenetic inactivation of the RASSF1A gene in hepatocellular carcinoma | Q73181730 |
| | Increased protein expression of DNA methyltransferase (DNMT) 1 is significantly correlated with the malignant potential and poor prognosis of human hepatocellular carcinomas | Q73311389 |
| | Expression and significance of new tumor suppressor gene PTEN in primary liver cancer | Q73437715 |
| | p73 is up-regulated in a subset of hepatocellular carcinomas | Q73520211 |
| | Modulation of p53 function in cellular regulation | Q73893385 |
| | Identification of homozygous deletions at chromosome 16q23 in aflatoxin B1 exposed hepatocellular carcinoma | Q74434735 |
| | Molecular pathogenesis of human hepatocellular carcinoma | Q74543031 |
| | Combined hypermethylation and chromosome loss associated with inactivation of SSI-1/SOCS-1/JAB gene in human hepatocellular carcinomas | Q74619820 |
| | Role of FHIT in human cancer | Q77766615 |
| | Expression and prognostic roles of the G1-S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence | Q77933504 |
| | The role of the FHIT/FRA3B locus in cancer | Q77936208 |
| | Expression of p33(ING1) in hepatocellular carcinoma: relationships to tumour differentiation and cyclin E kinase activity | Q78778832 |
| | Relationship between PTEN and VEGF expression and clinicopathological characteristics in HCC | Q79936859 |
| | Epigenetic and genetic alterations of PTEN in hepatocellular carcinoma | Q80175849 |
| | Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas | Q80238304 |
| | Aflatoxin B1 and polycyclic aromatic hydrocarbon adducts, p53 mutations and p16 methylation in liver tissue and plasma of hepatocellular carcinoma patients | Q82997793 |
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hepatocellular carcinoma | Q1148337 |
| P304 | page(s) | 1720-33 | |
| P577 | publication date | 2008-03-21 | |
| P1433 | published in | World Journal of Gastroenterology | Q15708885 |
| P1476 | title | Tumor suppressor and hepatocellular carcinoma | |
| P478 | volume | 14 | |